MAPT and Alzheimer disease: The studies have assessed core AD CSF biomarkers, with one study finding lower CSF amyloid-beta 42 (Aβ42) levels in patients with PD and worse olfaction, with no changes in total tau (T-tau) or phosphorylated tau (P-tau) [15].